Treating Peripheral Arterial Disease After Revascularization

Sonia Anand, MD, PhD, reviews the pathophysiology of peripheral artery disease (PAD) and lower extremity manifestations.

Marc Bonaca, MD, MPH, and Sonia Anand, MD, PhD, explain the comorbidities that increase patient risk for PAD.

Drs Bonaca and Anand discuss the incidence and clinical manifestations of PAD, including the rates of ischemic events and mortality.

Marc Bonaca, MD, MPH, elaborates on the costs associated with major atherothrombotic vascular events for patients with PAD after revascularization.

Manesh Patel, MD, and Marc Bonaca, MD, MPH, review the data from the CAPRIE and DAPT trials that studied therapeutic options for PAD.

Manesh Patel, MD, and Sonia Anand, MD, PhD, discuss the results of the EUCLID and COMPASS trials that studied PAD therapies.

Marc Bonaca, MD, MPH, explains the VOYAGER trial results and how they compare to the PAD trials that came before.

Drs Patel and Bonaca explain limited data results from some key trials, such as CASPAR and Dutch BOA, and apply them to antithrombotic therapy for patients with PAD in the post-vascularization setting.

Drs Patel, Anand, and Bonaca review the VOYAGER PAD trial, from study design to key data findings, and discuss its impact on the treatment of PAD.

Sonia Anand, MD, PhD, explains the current treatment options used in PAD therapy.

Marc Bonaca, MD, MPH, discusses unmet needs seen in the PAD therapeutic landscape.

Drs Anand and Bonaca end this Peer Exchange by giving some key takeaways to the audience and vascular physicians that treat PAD.